Loading...
Loading...
Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc.. Spoken Alpha tracks LABT's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks LABT's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 100% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LABT.
curl https://api.spokenalpha.com/v1/companies/LABT| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $5.46 | $4.49 | +21.6% | +5.0% | +6.6% |
| Q4 FY2026 | $5.22 | $4.35 | +20.1% | +1.9% | 0.0% |
| Q3 FY2026 | $5.11 | $4.36 | +17.2% | +0.9% | +1.2% |
| Q2 FY2026 | $5.33 | $4.45 | +19.7% | +5.4% | +7.5% |
| Q1 FY2025 | $5.83 | $4.46 | +30.7% | +2.9% | +5.8% |
| Q4 FY2025 | $6.03 | $4.60 | +31.1% | +2.9% | +2.0% |
| Q3 FY2025 | $5.70 | $4.48 | +27.3% | +6.5% | +5.7% |
| Q2 FY2025 | $5.57 | $4.60 | +21.0% | +6.8% | +4.8% |
| Q1 FY2024 | $5.79 | $4.59 | +26.2% | +7.6% | +7.6% |
| Q4 FY2024 | $5.65 | $4.68 | +20.7% | +2.7% | +4.6% |